Gene Biotherapeutics Inc
OTC:CRXM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gene Biotherapeutics Inc
OTC:CRXM
|
US |
|
Essensys PLC
LSE:ESYS
|
UK |
|
B
|
BizConf Telecom Co Ltd
SZSE:300578
|
CN |
|
L
|
Lyckegard Group AB
STO:LYGRD
|
SE |
|
Nigbas Nigde Beton Sanayii ve Ticaret AS
IST:NIBAS.E
|
TR |
|
MTU Aero Engines AG
XETRA:MTX
|
DE |
|
N
|
NextCell Pharma AB
STO:NXTCL
|
SE |
|
B
|
BAMPSL Securities Ltd
BSE:531591
|
IN |
Gene Biotherapeutics Inc
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company is headquartered in San Diego, California. The company went IPO on 2001-07-12. The firm is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for primarily for the treatment of cardiovascular disease. The Company’s technology platform is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Generx has been cleared Phase III clinical study, the AFFIRM study.
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company is headquartered in San Diego, California. The company went IPO on 2001-07-12. The firm is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for primarily for the treatment of cardiovascular disease. The Company’s technology platform is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Generx has been cleared Phase III clinical study, the AFFIRM study.
